Table 2.
Standardized prevalence ratios for malignancy in the IgG4-RD cohort compared to the general Chinese population
| Stratification variables | Observed malignancies, n | Chinese prevalence, % | Expected malignancies, n | SPR (95% CI) |
|---|---|---|---|---|
| Total | 29 | 0.556 | 3.347 | 8.66 (5.84, 12.31) |
| Sex | ||||
| Male | 18 | 0.2778 | 1.672 | 10.77 (6.41, 16.86) |
| Female | 11 | 0.2214 | 1.333 | 8.25 (4.14, 14.66) |
| Malignancy | ||||
| Lung | 8 | 0.0656 | 0.395 | 20.25 (8.77, 39.66) |
| Lymphoma | 3 | 0.0117 | 0.070 | 42.86 (8.79, 123.88) |
| Thyroid | 3 | 0.0299 | 0.180 | 16.67 (3.44, 48.47) |
| Cervix | 3 | 0.0233 | 0.140 | 21.43 (4.42, 62.21) |
| Bladder | 2 | 0.0173 | 0.104 | 19.23 (2.33, 69.07) |
| Stomach | 2 | 0.0648 | 0.390 | 5.13 (0.62, 18.44) |
IgG4-RD IgG4-related disease, SPR standardized prevalence ratio, 95% CI 95% confidence interval